IPO Timeline Raw facts
Broker Deadline
2026-06-02
Morning deadline
HKEX Deadline
2026-06-02
Noon deadline
Broker Results (T-2)
2026-06-03
Some brokers release in afternoon
Grey Market (T-1)
2026-06-04
Afternoon
HKEX Allotment (T-1)
2026-06-04
Evening
Registrar Allotment (T-1)
2026-06-04
Evening
Listing Day (T)
2026-06-05
First day of trading
Company Overview
| Stock Name | Longbio-B |
|---|---|
| Stock Code | 01779 |
| Company Full Name | LongBio Pharma (Suzhou) Co., Ltd. |
| Industry | Biotech & Pharma |
| Principal Activities | We are a clinical-stage biopharmaceutical company primarily focusing on in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases. Our Core Product, LP-003, is an anti-IgE antibody for allergic diseases including seasonal AR, CSU, allergic asthma, and CRSwNP. Our Key Product, LP-005, is a bi-functional antibody fusion protein targeting C5 and C3b complement for complement-mediated autoimmune diseases. We also have other pipeline products in pre-clinical stages. |
| Listing Date | 2026-06-05 |
| Listing Rules Era | New Rules (after Aug 2025) |
| Listing Rules Chapter | Chapter 18A Biotech |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 5th Floor, Building F, Area A No. 128 Yinhe Road, Dongnan Subdistrict Changshu City, Suzhou City, Jiangsu Province, PRC |
| Business Address (Hong Kong) | 40/F, Dah Sing Financial Centre 248 Queen's Road East, Wanchai, Hong Kong |
| Place of Incorporation | China |
| Listing Method | Global Offering (Public Offer + International Placing) |
| Listing Board | Main Board |
| Website | www.longbio.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | 卓佳证券登记有限公司，香港金钟道89号力宝中心1座31楼3101-3103室 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 96.06 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 50 shares |
| Entry Threshold | HK$ 4,803 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2026-05-28 to 2026-06-02 |
| Global Offering Shares | 14,193,150 shares |
| HK Public Offer Shares (Initial) | 1,419,350 shares (10.0%) |
| Public Offer Lots (Initial) | 28,387lots (14,193lots, 14,194lots) |
| International Placing Shares (Initial) | 12,773,800 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | SINOLINK SECURITIES (HONG KONG) COMPANY LIMITED CE AAI195 |
| Cornerstone Share | 94.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 1,363,393,989 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 50 | HK$ 4,803 |
| 2 lots | 100 | HK$ 9,606 |
| 3 lots | 150 | HK$ 14,409 |
| 4 lots | 200 | HK$ 19,212 |
| 5 lots | 250 | HK$ 24,015 |
| 6 lots | 300 | HK$ 28,818 |
| 7 lots | 350 | HK$ 33,621 |
| 8 lots | 400 | HK$ 38,424 |
| 9 lots | 450 | HK$ 43,227 |
| 10 lots | 500 | HK$ 48,030 |
| 12 lots | 600 | HK$ 57,636 |
| 14 lots | 700 | HK$ 67,242 |
| 16 lots | 800 | HK$ 76,848 |
| 18 lots | 900 | HK$ 86,454 |
| 20 lots | 1,000 | HK$ 96,060 |
| 30 lots | 1,500 | HK$ 144,090 |
| 40 lots | 2,000 | HK$ 192,120 |
| 50 lots | 2,500 | HK$ 240,150 |
| 60 lots | 3,000 | HK$ 288,180 |
| 70 lots | 3,500 | HK$ 336,210 |
| 80 lots | 4,000 | HK$ 384,240 |
| 90 lots | 4,500 | HK$ 432,270 |
| 100 lots | 5,000 | HK$ 480,300 |
| 120 lots | 6,000 | HK$ 576,360 |
| 140 lots | 7,000 | HK$ 672,420 |
| 160 lots | 8,000 | HK$ 768,480 |
| 180 lots | 9,000 | HK$ 864,540 |
| 200 lots | 10,000 | HK$ 960,600 |
| 400 lots | 20,000 | HK$ 1,921,200 |
| 600 lots | 30,000 | HK$ 2,881,800 |
| 800 lots | 40,000 | HK$ 3,842,400 |
| 1,000 lots | 50,000 | HK$ 4,803,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,200 lots | 60,000 | HK$ 5,763,600 |
| 1,400 lots | 70,000 | HK$ 6,724,200 |
| 1,600 lots | 80,000 | HK$ 7,684,800 |
| 1,800 lots | 90,000 | HK$ 8,645,400 |
| 2,000 lots | 100,000 | HK$ 9,606,000 |
| 4,000 lots | 200,000 | HK$ 19,212,000 |
| 6,000 lots | 300,000 | HK$ 28,818,000 |
| 8,000 lots | 400,000 | HK$ 38,424,000 |
| 10,000 lots | 500,000 | HK$ 48,030,000 |
| 12,000 lots | 600,000 | HK$ 57,636,000 |
| 14,193 lots | 709,650 | HK$ 68,168,979 |
Stock Connect Inclusion
| HK Market Cap | HK$ 10.84B |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | 18A Biotech |
|---|---|
| Est. Threshold | HK$ 10.47B Met |
| Analysis Result | 预计2026年9月7日入通 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not applicable (loss-making) |
| Profit/Loss Status | Net loss RMB 137.3 million |
| Period-End Cash Balance | RMB 95.05 million |
| Listing Expenses | ~HK$ 108,500,000 |
| Listing Expenses / Funds Raised | ~8.0% |
| Total Pre-IPO Investment | RMB 521.5 million |
First Day Performance
| First Day Close | Loading... |
|---|
Use of Proceeds
| Use of Proceeds | Approx. 75.0% for R&D and commercialization of Core Product and Key Product (34.0% for LP-003 R&D, 13.0% for LP-003 commercialization, 28.0% for LP-005 R&D); approx. 15.0% for other pre-clinical pipeline products and R&D platforms; approx. 10.0% for working capital and general corporate purposes. |
|---|
Underwriting Syndicate
Sole Sponsor (1)
SINOLINK SECURITIES (HONG KONG) COMPANY LIMITED CE AAI195(sole)
Overall Coordinators (6)
Joint Global Coordinators (6)
Joint Bookrunners (6)
Joint Lead Managers (6)
Capital Market Intermediaries (7)
Stabilizing Manager (1)
SINOLINK SECURITIES (HONG KONG) COMPANY LIMITED CE AAI195
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
ONC Lawyers 海润天睿律师事务所 |
| Legal Advisor to Sponsors/Underwriters |
Han Kun Law Offices LLP Zhong Lun Law Firm |
| Auditor and Reporting Accountant | Ernst & Young |
| Industry Advisor | Frost & Sullivan (Beijing) Inc., Shanghai Branch Co. |
| Compliance Advisor | Somerley Capital Limited CE BAU754 |
| Receiving Banks |
China CITIC Bank International Limited CMB Wing Lung Bank Limited |
| H Share Registrar | Tricor Investor Services Limited |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 等值美元）OrbiMed Funds | 18,000,000 USD | 1,467,050 | 10.34% | 1.98% | 6 months | 2026-12-05 |
| 2 | －OrbiMed Genesis | 11,900,000 USD | 969,900 | 6.84% | 1.31% | 6 months | 2026-12-05 |
| 3 | －BIOG | 6,100,000 USD | 497,150 | 3.50% | 0.67% | 6 months | 2026-12-05 |
| 4 | TruMed | 12,000,000 USD | 977,850 | 6.89% | 1.32% | 6 months | 2026-12-05 |
| 5 | －TruMed Innovation Fund.. | 8,500,000 USD | 692,650 | 4.88% | 0.93% | 6 months | 2026-12-05 |
| 6 | －TruMed Master Fund | 3,500,000 USD | 285,200 | 2.01% | 0.39% | 6 months | 2026-12-05 |
| 7 | 华泰资本投资及其最终客户 | 20,000,000 USD | 1,630,050 | 11.48% | 2.20% | 6 months | 2026-12-05 |
| 8 | －最终客户（高毅） | 12,000,000 USD | 978,050 | 6.89% | 1.32% | 6 months | 2026-12-05 |
| 9 | －最终客户（睿郡） | 8,000,000 USD | 652,000 | 4.59% | 0.88% | 6 months | 2026-12-05 |
| 10 | 睿远基金 | 10,000,000 USD | 815,050 | 5.75% | 1.09% | 6 months | 2026-12-05 |
| 11 | －Vision Fund 1 | 5,800,000 USD | 474,650 | 3.34% | 0.64% | 6 months | 2026-12-05 |
| 12 | －GSC Fund 1 | 3,200,000 USD | 258,900 | 1.83% | 0.35% | 6 months | 2026-12-05 |
| 13 | －Horizon Fund 1 | 500,000 USD | 40,750 | 0.29% | 0.05% | 6 months | 2026-12-05 |
| 14 | －Horizon Next Fund | 500,000 USD | 40,750 | 0.29% | 0.05% | 6 months | 2026-12-05 |
| 15 | 富国 | 10,000,000 USD | 815,000 | 5.74% | 1.10% | 6 months | 2026-12-05 |
| 16 | －富国基金 | 8,400,000 USD | 685,450 | 4.83% | 0.92% | 6 months | 2026-12-05 |
| 17 | －富国香港 | 1,600,000 USD | 129,550 | 0.91% | 0.18% | 6 months | 2026-12-05 |
| 18 | 惠理 | 8,000,000 USD | 651,900 | 4.59% | 0.88% | 6 months | 2026-12-05 |
| 19 | －惠理基金管理香港有限公司 | 7,000,000 USD | 570,400 | 4.02% | 0.77% | 6 months | 2026-12-05 |
| 20 | －惠理基金管理公司 | 1,000,000 USD | 81,500 | 0.57% | 0.11% | 6 months | 2026-12-05 |
| 21 | GBAHIL | 5,000,000 USD | 407,500 | 2.87% | 0.55% | 6 months | 2026-12-05 |
| 22 | FR M | 2,000,000 USD | 163,000 | 1.15% | 0.22% | 6 months | 2026-12-05 |
| 23 | 源峰远景成长基金及中国银河国际投资（就源峰场外掉期而言） | 2,000,000 USD | 163,000 | 1.15% | 0.22% | 6 months | 2026-12-05 |
Directors & Management
| Chairman | Dr. LIU Heng |
|---|---|
| Company Secretary | YUNG Mei Yee |
Executive Director (3)
| # | Name | English Name | Type |
|---|---|---|---|
| 1 | 刘恒 | — | Executive Director |
| 2 | 孙乃超 | — | Executive Director |
| 3 | 谢鸣 | — | Executive Director |
Non-Executive Director (4)
| # | Name | English Name | Type |
|---|---|---|---|
| 1 | 蔺剑 | — | Non-Executive Director |
| 2 | 顾勤 | — | Non-Executive Director |
| 3 | 薛涤 | — | Non-Executive Director |
| 4 | 陈侃 | — | Non-Executive Director |
Independent Non-Executive Director (4)
| # | Name | English Name | Type |
|---|---|---|---|
| 1 | 萧耀熙 | — | Independent Non-Executive Director |
| 2 | 阮添士 | — | Independent Non-Executive Director |
| 3 | 杨春 | — | Independent Non-Executive Director |
| 4 | 周国防 | — | Independent Non-Executive Director |
Major Shareholders
| Major Shareholders & Holdings | Dr. Liu (beneficial and through controlled corporation and acting-in-concert) holds approximately 44.16% pre-IPO; Ms. Lu Nan (spouse of Dr. Liu) deemed interested in 44.16%; Suzhou Taiwu (controlled by Dr. Liu) holds 8.17%; Dr. Sun holds 11.11% (plus through spouse and controlled corporations); Ms. Chow holds 6.07% (plus through spouse and controlled corporations); Shanghai Rising Suns (controlled by Ms. Chow) holds 3.59%; PharMab (controlled by Dr. Sun and Ms. Chow) holds 1.14%; Huzhou Youxing holds 11.70%; Suzhou Youxin holds 5.34%; OFC Bohui Fund holds 5.13%; Oriental Fortune Capital deemed interested in 7.08%. |
|---|
AI
AI 市场洞察
AI interpretation
deepseek-v4-pro · AI-generated
市场情绪
The IPO garnered an overwhelming oversubscription ratio of 4762.58x, reflecting extreme market enthusiasm. The overall hit rate of just 10.53% underscores intense competition for allocations, typical of a hot biotech listing. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
申购档位分析
甲尾 (A-tail) applicants with 50,000 lots received an expected 0.1785 lots, while 乙头 (B-head) applicants with 60,000 lots received a marginally higher 0.2401 lots. This narrow gap reveals an inefficient jump, as the additional 10,000 lots applied in B-tier yield only 0.0616 extra lots on average. (Broker fee structures vary and actual costs may differ. This analysis is for informational purposes only.)
申购人群画像
Mainland China participants accounted for 61.8% of total holders, signaling strong cross-border demand for this biotech IPO. The investor base skewed slightly male at 58.9% with an average age of 42.4, typical for risk-tolerant growth sectors. (Data may contain errors or omissions; verify against official HKEX filings. Not financial advice.)
